Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting glycosylated antigens on cancer cells using siglec‐7/9‐based CAR T‐cells

11 May 2020

Abstract excerpt

Chimeric antigen receptor (CAR) T-cells treatment demonstrate the increasing and powerful potential of immunotherapeutic strategies, as seen mainly for hematological malignancies. Still, efficient CAR-T cell approaches for the treatment of a broader spectrum of tumors are needed. It has been shown that cancer cells can implement strategies to evade immune response that include the expression of inhibitory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32391973
DOI: 10.1002/mc.23213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting glycosylated antigens on cancer cells using siglec‐7/9‐based CAR T‐cellsPMID 32391973Read ↗

Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.Semantic proximity Read ↗

A Developed NK-92MI Cell Line with Siglec-7neg Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells.Semantic proximity Read ↗

Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamilySemantic proximity Read ↗

Carbohydrate Targets for CAR T Cells in Solid Childhood CancersSemantic proximity Read ↗

Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancerSemantic proximity Read ↗

Cell-based production of Fc-GlcNAc and Fc-alpha-2,6 sialyl glycan enriched antibody with improved effector functions through glycosylation pathway engineeringSemantic proximity Read ↗

Cloning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic CellsSemantic proximity Read ↗

Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancersSemantic proximity Read ↗

Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric ReceptorSemantic proximity Read ↗

Sialyltransferases functions in cancersSemantic proximity Read ↗

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.Semantic proximity Read ↗

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform EngineeringSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.